Adjuvant therapy for colon cancer

Current Oncology Reports

Volumn 8, Issue 3, 2006, Pages 161-166

  Cilley, Jeffrey ^b   Mulcahy, Mary F ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAPECITABINE; CETUXIMAB; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; LOMUSTINE; OXALIPLATIN; SEMUSTINE;

ALOPECIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLON CANCER; COLON SURGERY; CYTOPENIA; DIARRHEA; DISEASE FREE SURVIVAL; DISEASE MARKER; DRUG DOSE REGIMEN; DRUG EFFICACY; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HIGH RISK POPULATION; HUMAN; LEUKEMIA; LEUKEMOGENESIS; METASTASIS; MICROSATELLITE INSTABILITY; MUCOSA INFLAMMATION; MYELOPROLIFERATIVE DISORDER; NAUSEA; NEPHROTOXICITY; NEUROTOXICITY; NEUTROPENIA; NONHUMAN; OVERALL SURVIVAL; PARESTHESIA; PREDICTION; PROGNOSIS; REVIEW; STATISTICAL SIGNIFICANCE; STOMATITIS; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COLONIC NEOPLASMS; FLUOROURACIL; HUMANS; MEDICAL ONCOLOGY; NEOPLASM METASTASIS;

EID: 33646251619     PISSN: 15233790     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11912-006-0015-7     Document Type: Review

References (32)

1. Jemal A, Murray T, Ward E, et al.: Cancer statistics, 2005. CA Cancer J Clin 2005, 55:10-30.
2. Greene FL, Page DL, Fleming ID et al., Eds. AJCC (American Joint Committee on Cancer) Cancer Staging Manual, edn 6. New York: Springer-Verlag; 2002.
3. Jessup JM, McGinnis LS, Steele GD Jr, et al.: The National Cancer Data Base. Report on colon cancer. Cancer 1996, 78:918-926.
4. Wolmark N, Fisher B, Rockette H, et al.: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988, 80:30-36.
5. Laurie JA, Moertel CG, Fleming TR, et al.: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989, 7:1447-1456.
6. Buyse M, Zeleniuch-Jacquotte A, Chalmers TC: Adjuvant therapy of colorectal cancer. Why we still don't know. JAMA 1988, 259:3571-3578.
7. Moertel CG, Fleming TR, Macdonald JS, et al.: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995, 122:321-326.
8. NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450.
9. O'Connell MJ, Mailliard JA, Kahn MJ, et al.: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997, 15:246-250.
10. Wolmark N, Rockette H, Fisher B, et al.: The benefit of leucovorin-modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993, 11:1879-1887.
11. Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995, 345:939-944.
12. O'Connell MJ, Laurie JA, Kahn M, et al.: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998, 16:295-300.
13. Wolmark N, Rockette H, Mamounas E, et al.: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999, 17:3553-3559.
14. Porschen R, Bermann A, Loffler T, et al.: Fluorouracil plus leucovorin as effective adjuvant chemotherapy in curatively resected stage III colon cancer: results of the trial adjCCA-01. J Clin Oncol 2001, 19:1787-1794.
15. Haller D, Catalano PJ, Macdonald JS, et al.: Phase III study of fluorouracil, leucovorin, and levamisole in high risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005, 23:5671-5678.
16. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000, 355:1588-1596.
17. Starling NEA: A randomised comparison between six months of bolus fluorouracil (5-FU)/ leucovorin (LV) and twelve weeks of protracted venous infusion (PVI) 5-FU as adjuvant treatment in colorectal cancer: an update with 5 years' follow-up [abstract]. Proc ASCO 2004, 23:3523.
18. Poplin EA, Benedetti JK, Estes NC, et al.: Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005, 23:1819-1825.
19. Andre T, Colin P, Louvet C, et al.: Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003, 21:2896-2903.
20. Twelves C, Wong A, Nowacki MP, et al.: Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005, 352:2696-2704.
21. Andre T, Boni C, Mounedji-Boudiaf L, et al.: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004, 350:2343-2351.
22. Wolmark N, Wieand JP, Kuebler JP, et al.: A phase III trial comparing FULV to FULV + oxaliplatin in stage II or III carcinoma of the colon: results of NSABP Protocol C-07 [abstract]. Proc ASCO 2005, 24:3500.
23. Saltz LB, Niedzwiecki D, Hollis RM, et al.: Irinotecan plus fluorouracil/ leucovorin (IFL) versus fluorouracil/leucovroin alone (FL) in stage III colon cancer (integroup trial CALGB C89803) [abstract]. Proc ASCO 2004, 23:3500.
24. van Cutsem E, Labianca D, Hossfeld G, et al.: Randomized phase III trial comparing infused irinotecan / 5-fluorouracil (5-FU)/folinic acid (IF) versus 5-FU/FA (F) in stage III colon cancer patients (pts). (PETACC 3) [abstract]. Proc ASCO 2005, 24:28.
25. Ychou M, Raoul J.-L, Douillard J.-Y: R LV5FU2 + CPT11 versus LV5FU2 alone in adjuvant colon cancer: interim safety results of the phase III randomized FNCLCC Accord02/FFCD9802 trial [abstract]. Proc ASCO 2003, 22:295.
26. Gray RG, Hills BR, Hills R, et al.: QUASAR: A randomized study of adjuvant chemotherapy versus observation including 3238 colorectal cancer patients [abstract]. Proc ASCO 2004, 23:A3501.
27. Mamounas E, Wieand S, Wolmark N, et al.: Comparative efficacy of adjuvant chemotherapy in patients with Dukes' B versus Dukes' C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03 and C-04). J Clin Oncol 1999, 17:1349-1355.
28. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999, 17L:1356-1363.
29. Benson AB III, Schrag D, Somerfield MR, et al.: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004, 22:3408-3419.
30. Swanson RS, Compton CC, Stewart AK, Bland KI: The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003, 10:65-71.
31. Ribic CM, Sargent DJ, Moore MJ, et al.: Tumor microsatelite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003, 349:247-257.
32. Watanabe T, Wu T-T, Catalano PJ, et al.: Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001, 344:1196-1206.